Category Ranking
98%
Total Visits
921
Avg Visit Duration
2 minutes
Citations
20
Article Abstract
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1111/all.16532 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Long-Term Open-Label Study Evaluating Oral Miglustat Treatment in Patients With Neuronal Ceroid Lipofuscinosis Type 3.
Neurology
October 2025
Neurology, Epilepsy and Movement Disorders Unit, Bambino Gesù Children's Hospital, IRCCS, Full Member of European Reference Network on Rare and Complex Epilepsies - EpiCARE, Rome, Italy.
Objectives: Neuronal ceroid lipofuscinosis type 3 (CLN3) is a rare lysosomal storage disorder characterized by progressive neurodegeneration. No disease-modifying treatments are currently available. Miglustat, a substrate reduction therapy, has shown preclinical efficacy in CLN3 models (conference abstract).
View Article and Find Full Text PDFOutcomes following transition from ibrutinib to zanubrutinib in patients with Waldenström macroglobulinemia from ASPEN.
Blood Adv
September 2025
Alfred Health and Monash University, East Melbourne, Australia.
Zanubrutinib is a next-generation covalent Bruton tyrosine kinase (BTK) inhibitor designed to provide complete and sustained BTK occupancy for efficacy across disease-relevant tissues, with fewer off-target adverse events (AEs) than other covalent BTK inhibitors. In the phase 3 ASPEN study (BGB-3111-302), comparable efficacy and a favorable safety profile versus ibrutinib were demonstrated in patients with MYD88-mutated Waldenström macroglobulinemia (WM), leading to approval of zanubrutinib for patients with WM. BGB-3111-LTE1 (LTE1) is a long-term extension study to which eligible patients, including patients from comparator treatment arms, could enroll following participation in various parent studies of zanubrutinib to treat B-cell malignancies.
View Article and Find Full Text PDFThe performance of an ophthalmic solution containing Poloxamer 407 and Polyquaternium 133 in reducing conjunctival bacterial load in patients receiving cataract surgery, a randomized trial.
Eur J Ophthalmol
September 2025
Department of Ophthalmology, Casilino General Hospital, Rome, Italy.
PurposeTo evaluate the safety and ability of an ophthalmic solution containing Poloxamer 407 and Polyquaternium 133 to reduce conjunctival bacterial load before cataract surgery.MethodsPatients (n = 74) were randomized to 2 groups: treatment (n = 37) or placebo (treatment's vehicle; (n = 37)) BID from V1 to V3. Patients were also given standard postoperative treatment from V2 to V3.
View Article and Find Full Text PDFPharmacokinetic Study and Bioequivalence Evaluation of Two Sustained-Release Tablets of Tamsulosin in Healthy Chinese Subjects Under Fasting and Postprandial Conditions.
Clin Pharmacol Drug Dev
September 2025
Phase I Clinical Research Centre, Wuhan Pulmonary Hospital, Wuhan, China.
Tamsulosin is a highly selective α1A adrenergic receptor antagonist that can relax smooth muscles in the urethra, bladder neck, and prostate and improve urinary disorders. It is therefore widely used to treat lower urinary tract symptoms caused by benign prostatic hyperplasia. The aim of this study is to evaluate the pharmacokinetic (PK) characteristics and bioequivalence of 2 different formulations (tamsulosin sustained-release tablets and tamsulosin sustained-release capsules) in healthy Chinese subjects.
View Article and Find Full Text PDFRandomized Clinical Trial on the Efficacy of Oral Tranexamic Acid Versus Topical Tranexamic Acid in Treatment of Melasma.
J Cosmet Dermatol
September 2025
Department of Medicine, Yazd Branch, Islamic Azad University, Yazd, Iran.
Background: Melasma is a prevalent skin condition that primarily affects females of reproductive age. Despite the various available treatments, managing melasma is challenging due to frequent relapses and partial responses. Tranexamic acid (TXA) has gained attention as a potential treatment because of its antifibrinolytic and anti-melanogenic properties.
View Article and Find Full Text PDF